NCT01588171View on ClinicalTrials.gov

Comparison of 2 Low Molecular Weight Heparin as a Thromboprophylaxis Postpartum

NACompletedINTERVENTIONAL
Enrollment

7,020

Participants

Timeline

Start Date

May 31, 2012

Primary Completion Date

October 31, 2013

Study Completion Date

November 30, 2013

Conditions
Venous Thromboembolic Diseases
Interventions
DRUG

Bemiparin

Bemiparin sodium 3,500 IU anti Xa/0.3 ml solution for injection in pre-filled syringe will be provided for each patient in Bemiparin group; subcutaneously 6 hours after delivery(vaginal and Caesarean)and then daily for up to 7 days.

DRUG

Enoxaparin

Enoxaparin sodium 40mg (equivalent to 4,000 IU anti-Xa activity) in 0.4ml water for injection will be administered subcutaneously 6 hours after the delivery( vaginal or abdominal)then daily up to 7 days post partum, for Enoxaparin group of patients.

Trial Locations (1)

383-65

Hawler medical university, Erbil

All Listed Sponsors
lead

Hawler Medical University

OTHER

NCT01588171 - Comparison of 2 Low Molecular Weight Heparin as a Thromboprophylaxis Postpartum | Biotech Hunter | Biotech Hunter